Core C: Biomarkers Core The goal of the Biomarkers Core (Core C) is to provide services for clinical correlates to the three projects of this program project grant. This will be achieved through the following specific aims: 1. To perform molecular assays for detecting hypoxic and oxidative damage in human tissues ex vivo, and in the animal models. These will include assays for serum markers of drug activity, and immunocytochemistry for proliferation markers, unique hypoxia and oxidation proteins, and cell death via apoptotic or other routes in Projects 1 and 2, as well as studies of hypoxic and oxidation imaging markers which are developed and validated in Project 3. 2. To develop and validate endpoints for assessment of therapeutic response in translational studies. The specific biomarkers to be analyzed by this core will include serum growth factors regulated by hypoxia, such as vascular endothelial growth factor (VEGF) (Projectl) serum thiols that may be altered by redox- active agents, such as glutathione (Project 2), imaging of animal models for therapeutic response to agents under investigation in Projects 1 and 2 (Project 3), and pharmacodynamic endpoints of hypoxia and redox targeted agents (all projects). Techniques are already in place for standardized sample collection, preparation and preservation, and sample analysis procedures for the assays described in this core. Additionally, we will continue to optimize new methods and assays to support the advancement of novel therapeutic agents into clinical trials. The core will work closely with the Clinical Trial Core (Core D) to coordinate and standardize sample collection and handling, and with the Biometry Core (Core B) to provide accurate raw data for analysis and interpretation. Collaboration between the projects will be facilitated by the standardized application of experimental assays developed within the projects to validation in pre-clinical and translation to clinical endpoints of hypoxia and redox targeted therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA017094-31
Application #
8136327
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
31
Fiscal Year
2010
Total Cost
$120,565
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Landowski, Terry H; Guntle, Gerald P; Zhao, Dezheng et al. (2016) Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Transl Oncol 9:228-35
Barrett, Harrison H; Alberts, David S; Woolfenden, James M et al. (2016) Therapy operating characteristic curves: tools for precision chemotherapy. J Med Imaging (Bellingham) 3:023502
Chang, Hae Ryung; Nam, Seungyoon; Kook, Myeong-Cherl et al. (2016) HNF4? is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut 65:19-32
Malm, Scott W; Hanke, Neale T; Gill, Alexander et al. (2015) The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res 34:31
Samulitis, Betty K; Pond, Kelvin W; Pond, Erika et al. (2015) Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biol Ther 16:43-51
Landowski, Terry H; Gard, Jaime; Pond, Erika et al. (2014) Targeting integrin ?6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther 13:1558-66
Nam, S; Chang, H R; Kim, K-T et al. (2014) PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene 33:4941-51
Dragovich, T; Laheru, D; Dayyani, F et al. (2014) Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol 74:379-87
Exley, Mark A; Hand, Laura; O'Shea, Donal et al. (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41-8
Zhang, Xiaomeng; Pagel, Mark D; Baker, Amanda F et al. (2014) Reproducibility of magnetic resonance perfusion imaging. PLoS One 9:e89797

Showing the most recent 10 out of 314 publications